Personalized Variable Versus Fixed Dose Glucocorticoid Therapy in AECOPD
Chronic Obstructive Pulmonary Disease
About this trial
This is an interventional treatment trial for Chronic Obstructive Pulmonary Disease focused on measuring Acute Exacerbations, Corticosteroids, Chronic Obstructive Pulmonary Disease, Doses
Eligibility Criteria
Inclusion Criteria:
- Exacerbation of COPD as defined by the presence of at least 2 of the following: change in baseline dyspnea, cough, or sputum quantity or purulence.
Exclusion Criteria:
- Signs of severe exacerbation (arterial pH < 7.26 or PaCO2 > 9.3 kPa)
- History of asthma
- Significant or unstable co-morbidity
- Participated in another study 4 weeks before admission
- Previously randomized to this study
- Known hypersensitivity to prednisolone
- Inability to give written informed consent
- Radiological diagnosis of pneumonia
- Estimated survival of less than 6 months due to severe comorbidity
- Use of glucocorticoid within 1 month before admission
Sites / Locations
- Daping Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
Other
Personalized variable dose of glucocorticoids arm
Fixed dose of glucocorticoids arm
Use of personalized variable dose of glucocorticoids according to a rating scale starting from the first day of hospitalization for 5 days, together with other necessary treatments, including antibiotics, Inhaled corticosteroid (ICS), long-acting beta2-agonist (LABA), Long-Acting Muscarinic Antagonists(LAMA), short-acting beta2-agonist (SABA), and other physical treatments.
Use of fixed term of glucocorticoids (40mg) starting from the first day of hospitalization for 5 days, together with other necessary treatments, including antibiotics, ICS, LABA, LAMA, SABA, and other physical treatments.